Bristol Myers Squibb (CELG-RI) Interest Expenses (2012 - 2013)
Bristol Myers Squibb (CELG-RI) reported Interest Expenses of $50.0 million for Q1 2013, up 19.05% year-over-year from $42.0 million in Q1 2012, and up 19.05% quarter-over-quarter from $42.0 million in Q1 2012.
Bristol Myers Squibb (CELG-RI) Interest Expenses (2012 - 2013) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 2 years of Interest Expenses data on file, last reported at $50.0 million in Q1 2013.
- Interest Expenses for Q1 2013 came in at $50.0 million, up 19.05% year-over-year; the trailing twelve-month figure through Dec 2013 was $50.0 million (up 19.05% YoY), and the FY2012 annual result was $182.0 million, up 25.52% from the prior year.
- Interest Expenses climbed to $50.0 million in Q1 2013 per CELG-RI's latest filing, from $42.0 million in the prior quarter.
- Over five years, Interest Expenses peaked at $50.0 million in Q1 2013 and troughed at $42.0 million in Q1 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -225.15 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 272.00 Mn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 657.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 240.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2013 | 50.00 Mn |
| Mar 31, 2013 | 50.00 Mn |
| Mar 31, 2012 | 42.00 Mn |
| Mar 31, 2012 | 42.00 Mn |